4 active not recruiting. 4 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Active not recruiting 4 |
| Phase 2 | 2 | Active not recruiting 2 |
Follow Blast Crisis: new trials by email Literature Review of Blast Crisis trials Research Report on Blast Crisis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia Autologous Anti-CD19/CD20/CD22 CAR T-cells, Biospecimen Collection, Bone Marrow Aspiration - Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Recurrent Acute Lymphoblastic Leukemia | Phase 1 | Active not recruiting | Ohio State University Comprehensive Cancer Center | 24 | 2026-01-14 | 2026-08-26 |
| Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia Bosutinib - Philadelphia Chromosome Positive CML, Accelerated Phase Chronic Myelogenous Leukemia | Phase 1 / Phase 2 | Active not recruiting | Children's Oncology Group | 60 | 2020-07-06 | 2026-10-01 |
| Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation Vorinostat, Blood and Marrow Transplant (BMT), Tacrolimus (or cyclosporine) - Hematologic Diseases, Acute Leukemia in Remission | Phase 1 / Phase 2 | Active not recruiting | University of Michigan Rogel Cancer Center | 43 | 2020-02-04 | 2026-01-27 |
| Hu8F4 in Treating Patients With Advanced Hematologic Malignancies Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4, Laboratory Biomarker Analysis, Pharmacological Study - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 72 | 2019-01-31 | 2026-09-18 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Leukemia, Myeloid, Accelerated Phase (2) · Leukemia, Myeloid, Chronic-Phase (2) · Lymphoma, Non-Hodgkin (2) · Graft vs Host Disease (1) · Hematologic Diseases (1) · Hematologic Neoplasms (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myelomonocytic, Chronic (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1) · Myelodysplastic Syndromes (1)
Bone Marrow Diseases (4) · Carcinogenesis (4) · Cell Transformation, Neoplastic (4) · Chronic Disease (4) · Disease Attributes (4) · Hemic and Lymphatic Diseases (4) · Leukemia (4) · Leukemia, Myeloid (4) · Myeloproliferative Disorders (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplastic Processes (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Hematologic Diseases (3)
Cyclophosphamide (2) · Biopsy (1) · Blood Component Removal (1) · Blood Specimen Collection (1) · Cyclosporine (1) · Magnetic Resonance Spectroscopy (1) · Methotrexate (1) · Mycophenolic Acid (1) · Specimen Handling (1) · Tacrolimus (1) · Vorinostat (1) · bosutinib (1) · fludarabine (1)
Children's Oncology Group (1) · M.D. Anderson Cancer Center (1) · Ohio State University Comprehensive Cancer Center (1) · University of Michigan Rogel Cancer Center (1)
United States (4) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · Spain (1) · Switzerland (1) · United Kingdom (1)
Sumithira Vasu, MD (1) · Sung W Choi, MD, MS (1) · Tapan M Kadia (1)
2015 (1), 2023 (1), P50CA100632 (1), UL1TR002240 (1)